Healthcare Providers and Services
Company Overview of Dominion Diagnostics, LLC
Dominion Diagnostics, LLC, a medical laboratory, provides clinical quantitative urine drug testing, medication monitoring, and support services in the United States. The company provides services to clients in various medical specialties, including pain medicine, primary care, addiction treatment, behavioral health, psychiatry, and hospital systems. It offers laboratory testing services, such as customized profiles and reports for individual patient monitoring, clinical assistance in results interpretation, reagents and instruments, biological monitoring and adulteration testing, rapid results through multiple reporting avenues, long-term specimen storage, comprehensive medication monitoring...
211 Circuit Drive
North Kingstown, RI 02852
Founded in 1997
Key Executives for Dominion Diagnostics, LLC
Vice President of Addiction Services
Compensation as of Fiscal Year 2014.
Dominion Diagnostics, LLC Key Developments
Dominion Diagnostics, LLC Enters into Exclusive Agreement with LifeGen, Inc. for Genetic Testing and Research
Dec 17 12
Dominion Diagnostics, LLC has entered into an exclusive agreement with LifeGen Inc. for the licensing rights to patented genetic testing. Currently the two companies are involved in a research study aimed at validating the testing against the Addiction Severity Index (ASI) designed and marketed by Inflexxion Inc. The research results are on track to be released in the first quarter of 2013, and are expected to show that LifeGen's test is valuable in determining a patient's Genetic Addiction Risk Score (GARS), or relative predisposition in manifesting addictive behaviors. Approximately 400 patient subjects selected from addiction treatment facilities across the country are involved in the GARS analysis. The GARS analysis is set to investigate a panel of genes primarily involved in brain reward circuitry. For 30% of the human population (approximately 100 million people), genetics are a large factor in dopamine-driven addiction. This subset of the population carries the DRD2 Type A1 receptor gene which induces low dopamine brain function that results in the propensity for addictive cravings. The GARS test involves a number of reward genes and related polymorphisms which have significant impact on substance use disorders. LifeGen's Kenneth Blum, PhD is the primary investigator on the companies' current research. Blum is credited with the first known association of the dopamine D2 receptor (DRD2) gene with alcoholism and other addictive behaviors including drug addiction, smoking, overeating, gambling, and sex (Blum & Noble, JAMA, 1990).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries